<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AID</journal-id><journal-title-group><journal-title>Advances in Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-2648</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/aid.2022.121003</article-id><article-id pub-id-type="publisher-id">AID-115079</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Black Water Fever in Severe Falciparum Malaria: A Case Report
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ali</surname><given-names>Sher</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Saif</surname><given-names>A. Latif</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>North Khaitan Clinic, Ministry of Health, Kuwait City, Kuwait</addr-line></aff><aff id="aff1"><addr-line>Infectious Diseases Hospital, Ministry of Health, Kuwait City, Kuwait</addr-line></aff><pub-date pub-type="epub"><day>21</day><month>01</month><year>2022</year></pub-date><volume>12</volume><issue>01</issue><fpage>42</fpage><lpage>49</lpage><history><date date-type="received"><day>22,</day>	<month>December</month>	<year>2021</year></date><date date-type="rev-recd"><day>6,</day>	<month>February</month>	<year>2022</year>	</date><date date-type="accepted"><day>9,</day>	<month>February</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Black water fever (BWF) is a complication of severe
  <em> Plasmodium falciparum</em> infection in hemolysis of erythrocytes into the bloodstream releasing the hemoglobin directly into the blood vessels and causes severe anemia and passage of dark/cola color urine, leading to acute renal failure. Hemoglobinuria or BWF is a rare and severe manifestation of falciparum malaria characterized by sudden intravascular hemolysis followed by fever and presence of abnormal hemoglobin in the urine.
   Aim: The aim of this study was to diagnose and treat severe malaria infection in a Nigerian patient admitted to the Casualty of the IDH Hospital.
   Case Presentation: A 20-year-old Nigerian boy came to Kuwait and started complaining abdominal pain, nausea, vomiting and fever two days after his arrival. The investigation revealed high fever (40.8
  &amp;#730;C), heart rate 125, blood pressure of 100/60 mmHg. The physical examination was unremarkable, including a normal neurologic examination, no hepatosplenomegaly, rash and neck rigidity. The Giemsa stained thick and thin blood examination confirmed the severe infection of 
  <em>Plasmodium falciparum</em> with 41.0% parasitemia. The patient was admitted to the hospital and started intravenous Quinine (1200 mg loading dose in 5% glucose over 4 hours). The patient was feeling much better on next morning but became unconscious by evening and shifted to ICU. His all CBC parameters were higher and started passing dark/cola color urine. The 12 units of whole blood were exchanged on next morning and became fully conscious on 4
  <sup>th</sup> day and his anemia and thrombocytopenia were improved and the color of the urine also became normal. 
  Conclusion: Quinine is used in both complicated and uncomplicated malaria and may cause black water fever in severe infection of 
  <em>P. falciparum</em>. It is caused by the hemolysis of erythrocytes due to malaria and also with the metabolism of quinine, making these cells more vulnerable to hemolysis in falciparum malaria and also in G6PD deficiency.
 
</p></abstract><kwd-group><kwd>Black Water Fever</kwd><kwd> Hemoglobinuria</kwd><kwd> Malaria</kwd><kwd> Quinine</kwd><kwd> Chloroquine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Background</title><p>Black water fever, also called malarial hemoglobinuria, is one of the less common yet most dangerous complications of malaria. The term black water fever (BWF) has been taken from the French word “fi&#232;vre bilieuse m&#233;lanurique” [<xref ref-type="bibr" rid="scirp.115079-ref1">1</xref>] , generally used for a febrile syndrome with intermittent passage of dark-red to black colored urine in falciparum malaria at very high parasitaemia on peripheral blood smear and the symptoms of renal failure, circulatory compromise, pallor, jaundice, nausea, vomiting, and epigastric pain [<xref ref-type="bibr" rid="scirp.115079-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref3">3</xref>] .</p><p>BWF is mostly associated with Plasmodium falciparum infection [<xref ref-type="bibr" rid="scirp.115079-ref4">4</xref>] , but cases have also been documented in Plasmodium vivax [<xref ref-type="bibr" rid="scirp.115079-ref5">5</xref>] or in a mixed infection of P. falciparum and P. vivax, Plasmodium malariae [<xref ref-type="bibr" rid="scirp.115079-ref3">3</xref>] , and Plasmodium knowlesi infections [<xref ref-type="bibr" rid="scirp.115079-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref7">7</xref>] . In the beginning of twentieth century, the number of BWF cases was very high due to the use of Quinine as a treatment of malaria. There was a dramatic decrease in the incidence of BWF when chloroquine superseded quinine in 1950 and the reemergence of BWF following the reintroduction of quinine due to chloroquine resistance and introduction of mefloquine and halofantrine both strongly suggested that amino-alcohol drugs play a role in the etiology of BWF [<xref ref-type="bibr" rid="scirp.115079-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref12">12</xref>] . The massive hemolysis of red blood cells occurs in severe Plasmodium falciparum infection when treated with amino-alcohol drugs, like, quinine. In severe falciparum malaria, the mortality rate is very high (20% to 30%) and even higher among non-immune patients.</p><p>Generally, the anti-malarial therapy by quinine could be a cause of BWF syndrome in severe falciparum malaria. The mechanism of intra-vascular hemolysis in G6PD-deficient patients as a response to primaquine-induced oxidative stress is well known [<xref ref-type="bibr" rid="scirp.115079-ref12">12</xref>] . Stephens [<xref ref-type="bibr" rid="scirp.115079-ref13">13</xref>] has summarized several reports associating quinine with BWF in patients with severe malaria in G6PD-deficient patients. Very little is known about the use of artemisinin (ART) or its derivatives [<xref ref-type="bibr" rid="scirp.115079-ref14">14</xref>] and their association with BWF, either alone or as part of artemisinin-based combination therapy (ACT) despite its high oxidative potential [<xref ref-type="bibr" rid="scirp.115079-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref17">17</xref>] . BWF has also been reported with other amino-alcohol drugs such as halofantrine [<xref ref-type="bibr" rid="scirp.115079-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref20">20</xref>] , mefloquine [<xref ref-type="bibr" rid="scirp.115079-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref10">10</xref>] and lumefantrine, a related aryl-amino-alcohol compound [<xref ref-type="bibr" rid="scirp.115079-ref16">16</xref>] . The BWF was not reported by chloroquine [<xref ref-type="bibr" rid="scirp.115079-ref3">3</xref>] or piperaquine derivatives in severe falciparum malaria despite its extensive use [<xref ref-type="bibr" rid="scirp.115079-ref21">21</xref>] .</p><p>We present a rare case of black water fever developed in a Nigerian patient in a non-endemic malaria country, Kuwait, on second day of quinine treatment in severe falciparum malaria.</p></sec><sec id="s2"><title>2. Case Summary</title><p>A 20-year-old Nigerian boy came to Kuwait on 16<sup>th</sup> September 2014 and he was complaining abdominal pain, nausea, vomiting and fever two days after his arrival. He has visited IDH casualty on 22<sup>nd</sup> September and his initial parameters registered like, high fever (40.8C), heart rate 125, blood pressure of 100/60 mmHg. The physical examination was unremarkable, including a normal neurologic examination, no hepatosplenomegaly, rash and neck rigidity. The initial laboratory tests revealed mild anemia (Hb, 126 g/L and HTC, 0.352 L/L, RBC, 4.12 &#215; 10<sup>12</sup>/L, WBC, 4.2 &#215; 10<sup>9</sup>/L and platelets 16 &#215; 10<sup>9</sup>/L) (<xref ref-type="table" rid="table1">Table 1</xref>). Most of his biological parameters, like liver enzymes, glucose, creatinine and total bilirubin were higher (<xref ref-type="table" rid="table2">Table 2</xref>). His G6PD was normal, 214.6 mU/10<sup>9</sup> erythrocytes, (normal range 165 - 365 mU/10<sup>9</sup> erythrocytes) and Pro-calcitonin was very high 125.4 (normal range 0 - 0.05) (<xref ref-type="table" rid="table3">Table 3</xref>). Giemsa stained thick and thin blood</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Hematological parameters during the treatment</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameters</th><th align="center" valign="middle" >Day 0</th><th align="center" valign="middle" >Day 1</th><th align="center" valign="middle" >Day 2</th><th align="center" valign="middle" >Day 3</th><th align="center" valign="middle" >Day 4</th><th align="center" valign="middle" >Day 5</th><th align="center" valign="middle" >Day 6</th><th align="center" valign="middle" >Day 7</th><th align="center" valign="middle" >Day 30</th></tr></thead><tr><td align="center" valign="middle" >RBC</td><td align="center" valign="middle" >4.12↓</td><td align="center" valign="middle" >3.8↓</td><td align="center" valign="middle" >3.11↓</td><td align="center" valign="middle" >3.07↓</td><td align="center" valign="middle" >3.15↓</td><td align="center" valign="middle" >3.12↓</td><td align="center" valign="middle" >3.26↓</td><td align="center" valign="middle" >3.2↓</td><td align="center" valign="middle" >4.05↓</td></tr><tr><td align="center" valign="middle" >WBC</td><td align="center" valign="middle" >3.5↓</td><td align="center" valign="middle" >6.71</td><td align="center" valign="middle" >6.1</td><td align="center" valign="middle" >7.9</td><td align="center" valign="middle" >10.6</td><td align="center" valign="middle" >12.6↑</td><td align="center" valign="middle" >15.8↑</td><td align="center" valign="middle" >15.2↑</td><td align="center" valign="middle" >6.5</td></tr><tr><td align="center" valign="middle" >HB</td><td align="center" valign="middle" >12.6↓</td><td align="center" valign="middle" >11.2↓</td><td align="center" valign="middle" >9.1↓</td><td align="center" valign="middle" >9.0↓</td><td align="center" valign="middle" >9.3↓</td><td align="center" valign="middle" >9.2↓</td><td align="center" valign="middle" >9.6↓</td><td align="center" valign="middle" >9.7↓</td><td align="center" valign="middle" >12.4↓</td></tr><tr><td align="center" valign="middle" >Platelets</td><td align="center" valign="middle" >16↓</td><td align="center" valign="middle" >27↓</td><td align="center" valign="middle" >19↓</td><td align="center" valign="middle" >19↓</td><td align="center" valign="middle" >28↓</td><td align="center" valign="middle" >96↓</td><td align="center" valign="middle" >148↓</td><td align="center" valign="middle" >224</td><td align="center" valign="middle" >195</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Biochemical laboratory values during treatment</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameters</th><th align="center" valign="middle" >Day 0</th><th align="center" valign="middle" >Day 1</th><th align="center" valign="middle" >Day 2</th><th align="center" valign="middle" >Day 3</th><th align="center" valign="middle" >Day 4</th><th align="center" valign="middle" >Day 5</th><th align="center" valign="middle" >Day 6</th><th align="center" valign="middle" >Day 7</th><th align="center" valign="middle" >Day 8</th><th align="center" valign="middle" >Day 30</th></tr></thead><tr><td align="center" valign="middle" >Glucose</td><td align="center" valign="middle" >4.9</td><td align="center" valign="middle" >16.95↑</td><td align="center" valign="middle" >9.32↑</td><td align="center" valign="middle" >8.67↑</td><td align="center" valign="middle" >7.1↑</td><td align="center" valign="middle" >5.91</td><td align="center" valign="middle" >6.5↑</td><td align="center" valign="middle" >9.12↑</td><td align="center" valign="middle" >6.91↑</td><td align="center" valign="middle" >5.88</td></tr><tr><td align="center" valign="middle" >Na</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >134.9</td><td align="center" valign="middle" >134.8</td><td align="center" valign="middle" >134.6</td><td align="center" valign="middle" >132.4</td><td align="center" valign="middle" >134.4</td><td align="center" valign="middle" >131.7</td><td align="center" valign="middle" >130.6</td><td align="center" valign="middle" >133.3</td><td align="center" valign="middle" >138.5</td></tr><tr><td align="center" valign="middle" >K</td><td align="center" valign="middle" >3.45</td><td align="center" valign="middle" >5.29</td><td align="center" valign="middle" >3.73</td><td align="center" valign="middle" >4.05</td><td align="center" valign="middle" >4.01</td><td align="center" valign="middle" >3.97</td><td align="center" valign="middle" >3.82</td><td align="center" valign="middle" >4.2</td><td align="center" valign="middle" >4.56</td><td align="center" valign="middle" >3.83</td></tr><tr><td align="center" valign="middle" >Total Bilirubin</td><td align="center" valign="middle" >117.3↑</td><td align="center" valign="middle" >102.3↑</td><td align="center" valign="middle" >84.7↑</td><td align="center" valign="middle" >40.2↑</td><td align="center" valign="middle" >43.4↑</td><td align="center" valign="middle" >30.5↑</td><td align="center" valign="middle" >22.9↑</td><td align="center" valign="middle" >21↑</td><td align="center" valign="middle" >26.5↑</td><td align="center" valign="middle" >5.7</td></tr><tr><td align="center" valign="middle" >CO<sub>2</sub></td><td align="center" valign="middle" >22.2</td><td align="center" valign="middle" >27.8</td><td align="center" valign="middle" >24.3</td><td align="center" valign="middle" >20.6</td><td align="center" valign="middle" >22.7</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >22.2</td><td align="center" valign="middle" >23.2</td><td align="center" valign="middle" >25.6</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >Creatinine</td><td align="center" valign="middle" >139↑</td><td align="center" valign="middle" >122↑</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >95</td></tr><tr><td align="center" valign="middle" >Urea</td><td align="center" valign="middle" >7.8</td><td align="center" valign="middle" >5.7</td><td align="center" valign="middle" >5.6</td><td align="center" valign="middle" >3.5</td><td align="center" valign="middle" >3.8</td><td align="center" valign="middle" >3.7</td><td align="center" valign="middle" >3.30</td><td align="center" valign="middle" >2.4</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >3.5</td></tr><tr><td align="center" valign="middle" >ALT</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >106↑</td><td align="center" valign="middle" >102↑</td><td align="center" valign="middle" >99↑</td><td align="center" valign="middle" >28</td></tr><tr><td align="center" valign="middle" >AST</td><td align="center" valign="middle" >80↑</td><td align="center" valign="middle" >102↑</td><td align="center" valign="middle" >106↑</td><td align="center" valign="middle" >50↑</td><td align="center" valign="middle" >49↑</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >98↑</td><td align="center" valign="middle" >70↑</td><td align="center" valign="middle" >53↑</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >Alkaline Phosphatase</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >157↑</td><td align="center" valign="middle" >149↑</td><td align="center" valign="middle" >153↑</td><td align="center" valign="middle" >104</td></tr><tr><td align="center" valign="middle" >LDH</td><td align="center" valign="middle" >654↑</td><td align="center" valign="middle" >1114↑</td><td align="center" valign="middle" >1251↑</td><td align="center" valign="middle" >574↑</td><td align="center" valign="middle" >531↑</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >484↑</td><td align="center" valign="middle" >417↑</td><td align="center" valign="middle" >380↑</td><td align="center" valign="middle" >159↑</td></tr><tr><td align="center" valign="middle" >GGT</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >58↑</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >235↑</td><td align="center" valign="middle" >225↑</td><td align="center" valign="middle" >199↑</td><td align="center" valign="middle" >48</td></tr></tbody></table></table-wrap><p>smears, and immunochromatographic (ICT) malaria test for the detection of histidine rich protein-2 (HRP2) antigen were used for the diagnosis of malaria. The ICT assay was performed as described by following the manufacturer’s instructions. The Giemsa stained peripheral blood smears revealed the presence of all the sexual stages of Plasmodium falciparum (rings, trophozoites, and schizonts) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Rapid immunochromatographic test for histidine rich protein-2 (HRP2) (AccuBio Tech Co., Ltd Bejing, China) was also positive (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The immunochromatographic test detects antigen in blood samples only if the parasite count is about 100 or more/μl of blood [<xref ref-type="bibr" rid="scirp.115079-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref23">23</xref>] . The Giemsa stained thick and thin blood films examination confirmed the severe infection of Plasmodium falciparum with 41.0% parasitemia. The patient was admitted to the hospital and started intravenous Quinine (1200 mg loading dose in 5% glucose over 4 hours). The patient was feeling much better on next morning but became unconscious by evening and shifted to ICU. His all CBC parameters were higher and started passing dark/cola color urine. The 12 units of whole blood was exchanged on 24<sup>th</sup> September at morning time. He became fully conscious on 4<sup>th</sup> day and his anemia and thrombocytopenia was improved and the color of the urine also became normal. He was transferred to the general ward on 7<sup>th</sup> day and discharged from the hospital on 9<sup>th</sup> day without any symptoms of malaria.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Key biochemical laboratory values during treatment</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameters</th><th align="center" valign="middle" >Day 0</th><th align="center" valign="middle" >Day 1</th><th align="center" valign="middle" >Day 2</th><th align="center" valign="middle" >Day 3</th><th align="center" valign="middle" >Day 4</th><th align="center" valign="middle" >Day 5</th><th align="center" valign="middle" >Day 6</th><th align="center" valign="middle" >Day 7</th><th align="center" valign="middle" >Day 30</th></tr></thead><tr><td align="center" valign="middle" >Procalcitonin</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >125.4↑ (0 - 0.5)</td><td align="center" valign="middle" >88.57↑</td><td align="center" valign="middle" >35.1↑</td><td align="center" valign="middle" >15.0↑</td><td align="center" valign="middle" >8.36↑</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Lactate</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.19 (0.5 - 2.2)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >G6PD act.</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >214.6 (165 - 365)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Parasitemia</td><td align="center" valign="middle" >41%</td><td align="center" valign="middle" >20.0%</td><td align="center" valign="middle" >1.2%</td><td align="center" valign="middle" >0.2%</td><td align="center" valign="middle" >0.1%</td><td align="center" valign="middle" >0.01%</td><td align="center" valign="middle" >Neg</td><td align="center" valign="middle" >Neg</td><td align="center" valign="middle" >Neg</td></tr></tbody></table></table-wrap></sec><sec id="s3"><title>3. Discussion</title><p>Black water fever mostly occurs in Plasmodium falciparum infection and has a very high mortality rate. The symptoms developed in BWF are rapid pulse, high fever and chills, extreme prostration, a rapidly developing anemia, and the passage of urine that is dark black or cola in color. The dark/cola color of the urine is due to the presence of large amounts of hemoglobin released during the excessive destruction of the patient’s erythrocytes by malarial parasites and causing severe anemia. The presence of blood pigments in the blood circulation usually produces jaundice early in the course of the disease.</p><p>Black water fever is mostly prevalent in Africa and Southeast Asia. The non-immune immigrants or individuals who are chronically exposed to malaria are the main vulnerable to infection and the victims of the complications. Black water fever seldom appears until a person has had at least four or more attacks of malaria and has been in an endemic area for six months. This patient came from the Nigeria with the history of several episodes of malaria. He was admitted in the hospital with fever, jaundice and body ache. The Giemsa stained thick and thin blood films were positive for P. falciparum and revealed all the stages of P. falciparum with 41% parasitemia. The treatment with quinine was started and after 12 hours the patient started passing dark/cola color urine and an increase of jaundice level. The treatment with quinine was suspended and coartem was started (four tablets as a single initial dose, 4 tablets again after 8 hours, and then 4 tablets twice-daily (morning and evening) for the following 2 days (total course of 24 tablets). The red blood cells and platelets were transfused and hemodialysis and plasmapheresis were also performed. The patient was discharged on 9<sup>th</sup> day when he became asymptomatic and his Giemsa stained blood films became negative. Treatment for black water fever includes antimalarial drugs, whole-blood transfusions, and complete bed rest, but even with these measures the mortality remains about 25 to 50 percent.</p><p>The black water fever is caused by the hemolysis of erythrocytes due to malaria and also with the metabolism of quinine by the cytochrome P450 3A4 enzyme responsible for increasing oxidative stress within erythrocytes, making these cells more vulnerable to hemolysis with falciparum malaria and G6PD deficiency. Oxidative stress is one of the major contributors to the manifestations of BWF in South Vietnam [<xref ref-type="bibr" rid="scirp.115079-ref24">24</xref>] . The prevalence of G6PD deficiency amongst malaria cases is high in this region and a few cases have G6PD mutants of diminished function in the presence of apparently normal G6PD levels [<xref ref-type="bibr" rid="scirp.115079-ref8">8</xref>] . The metabolites of quinine may exert oxidative stress under particular conditions with acute hemolysis observed in G6PD deficient patients exposed to primaquine [<xref ref-type="bibr" rid="scirp.115079-ref24">24</xref>] .</p><p>An alternate possibility is that anti-malarial drugs and the effects of immunity are the true cause of BWF. P. falciparum infections in human has severe effects on RBC function including changes in RBC size, deformability, endothelial adhesion and up regulation of particular outer membrane proteins including the ring-infected erythrocyte surface antigen (RESA) [<xref ref-type="bibr" rid="scirp.115079-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.115079-ref26">26</xref>] . In acute P. falciparum malaria the RESA is present on even non-parasitized RBCs, suggesting a circulating population of RBC “survivors” from which parasites have been removed by the spleen. This is thought to be why the fall in hematocrit seen in falciparum malaria is less than it would be predicted by the number of parasitized RBCs. In some circumstances it may be that once-infected erythrocytes (o-iE) become fatally inclined to non-immune oxidative hemolysis and this is done by anti-malarial drug therapy, in this case artemether with lumefantrine. This hypothesis gives very provocative information that BWF could be a deciding factor in a small number of patients who control an initial parasitemia at the expense of RBC predisposition to non-immune intravascular lysis that mimics or is caused by oxidative stress.</p></sec><sec id="s4"><title>4. Conclusion</title><p>Quinine is managing both complicated and uncomplicated malaria and may precipitate black water fever in severe infection of P. falciparum. The black water fever is caused by the hemolysis of erythrocytes due to malaria and also with the metabolism of quinine by the cytochrome P450 3A4 enzyme responsible for increasing oxidative stress within erythrocytes, making these cells more vulnerable to hemolysis with falciparum malaria in G6PD deficient patients.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We would like to thank the technicians from hematology section of the IDH Laboratories and also the doctors working in ward 5 and ICU of Infectious Diseases Hospital for their help. We would also like to thank Prof. and Chairman, Abu Salim Mustafa, Department of Microbiology, Faculty of Medicine for reading and suggestions of the manuscript.</p></sec><sec id="s6"><title>Funding</title><p>This research received no external funding.</p></sec><sec id="s7"><title>Informed Consent Statement</title><p>Not applicable.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Sher, A. and Latif, S.A. (2022) Black Water Fever in Severe Falciparum Malaria: A Case Report. Advances in Infectious Diseases, 12, 42-49. https://doi.org/10.4236/aid.2022.121003</p></sec></body><back><ref-list><title>References</title><ref id="scirp.115079-ref1"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Easmon</surname><given-names> J.F. </given-names></name>,<etal>et al</etal>. (<year>1885</year>)<article-title>Notes of a Case of Black Water Fever with Remarks (I. The So-Called Fièvre Bilieuse Mélanurique or Hématurique of French Writers)</article-title><source> Med Times</source><volume> 2</volume>,<fpage> 277</fpage>-<lpage>280</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.115079-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bruce-Chwatt, L.J. and de Zulueta, J. (1980) The Rise and Fall of Malaria in Europe: A Historico-Epidemiological Study. Oxford University Press, Oxford.</mixed-citation></ref><ref id="scirp.115079-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Van den Ende, J., Coppens, G., Verstraeten, T., Van Haegenborgh, T., Depraetere, K., Van Gompel, A., et al. (1998) Recurrence of Black Water Fever: Triggering of Relapses by Different Antimalarials. Tropical Medicine &amp; International Health, 3, 632-639. https://doi.org/10.1046/j.1365-3156.1998.00287.x</mixed-citation></ref><ref id="scirp.115079-ref4"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Plehn</surname><given-names> A. </given-names></name>,<etal>et al</etal>. (<year>1920</year>)<article-title>Neue Untersuchungen über die Entstehungsweise des Schwarzwassenfiebers</article-title><source> Arch Schiff Tropen Hyg</source><volume> 24</volume>,<fpage> 321</fpage>-<lpage>326</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.115079-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Katongole-Mbidde, E., Banura, C. and Kizito, A. (1988) Black Water Fever Caused by Plasmodium vivax Infection in the Acquired Immune Deficiency Syndrome. BMJ, 296, 827. https://doi.org/10.1136/bmj.296.6625.827</mixed-citation></ref><ref id="scirp.115079-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Barber, B.E., William, T., Grigg, M.J., Menon, J., Auburn, S., Marfurt, J., et al. (2013) A Prospective Comparative Study of knowlesi, falciparum and vivax Malaria in Sabah, Malaysia: High Proportion with Severe Disease from Plasmodium knowlesi and P. vivax but No Mortality with Early Referral and Artesunate Therapy. Clinical Infectious Diseases, 56, 383-397. https://doi.org/10.1093/cid/cis902</mixed-citation></ref><ref id="scirp.115079-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Barber, B.E., Grigg, M.J., William, T., Yeo, T.W. and Anstey, N.M. (2016) Intravascular Haemolysis with Haemoglobinuria in a Splenectomized Patient with Severe Plasmodium knowlesi Malaria. Malaria Journal, 15, Article No. 462. https://doi.org/10.1186/s12936-016-1514-0</mixed-citation></ref><ref id="scirp.115079-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chau, T.T.H., Day, N.P., Van Chuong, L., Mai, N.T.H., Loc, P.P., Phu, N.H., et al. (1996) Black Water Fever in Southern Vietnam: A Prospective Descriptive Study of 50 Cases. Clinical Infectious Diseases, 23, 1274-1281. https://doi.org/10.1093/clinids/23.6.1274</mixed-citation></ref><ref id="scirp.115079-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bisoffi, Z., Marocco, S., Monteiro, G. and Marsiaj, M. (1999) Acute Intravascular Haemolysis (Black Water Fever) after Antimalarial Treatment. Tropical Medicine &amp; International Health, 4, 72-73.</mixed-citation></ref><ref id="scirp.115079-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bruneel, F., Gachot, B., Wolff, M., Régnier, B., Danis, M. and Vachon, F. (2001) Resurgence of Black Water Fever in Long Term European Expatriates in Africa: Report of 21 Cases and Review. Clinical Infectious Diseases, 32, 1133-1140. https://doi.org/10.1086/319743</mixed-citation></ref><ref id="scirp.115079-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Rogier, C., Imbert, P., Tall, A., Sokhna, C., Spiegel, A. and Trape, J.-F. (2003) Epidemiological and Clinical Aspects of Black Water Fever among African Children Suffering Frequent Malaria Attacks. Transactions of the Royal Society of Tropical Medicine and Hygiene, 97, 193-197. https://doi.org/10.1016/S0035-9203(03)90116-7</mixed-citation></ref><ref id="scirp.115079-ref12"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Georges</surname><given-names> C.R.P. </given-names></name>,<etal>et al</etal>. (<year>2009</year>)<article-title>Black Water Fever: The Rise and Fall of an Exotic Disease</article-title><source> Journal of Nephrology</source><volume> 22</volume>,<fpage> 120</fpage>-<lpage>128</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.115079-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Stephens, J.W.W. (1937) Black Water Fever: A Historical Survey and Summary of Observations Made over a Century. University Press of Liverpool, London.</mixed-citation></ref><ref id="scirp.115079-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Carson, P.E., Larkin Flanagan, C., Ickes, C.E. and Alving, A.S. (1956) Enzymatic Deficiency in Primaquine-Sensitive Erythrocytes. Science, 124, 484-485. https://doi.org/10.1126/science.124.3220.484.b</mixed-citation></ref><ref id="scirp.115079-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Price, R., van Vugt, M., Phaipun, L., Luxemburger, C., Simpson, J., McGready, R., et al. (1999) Adverse Effects in Patients with Acute Falciparum Malaria Treated with Artemisinine Derivatives. American Journal of Tropical Medicine and Hygiene, 60, 547-555. https://doi.org/10.4269/ajtmh.1999.60.547</mixed-citation></ref><ref id="scirp.115079-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Dondorp, A., Nosten, F., Stepniewska, K., Day, N. and White, N. (2005) South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group. Artesunate versus Quinine for Treatment of Severe Falciparum Malaria: A Randomised Trial. The Lancet, 366, 717-725. https://doi.org/10.1016/S0140-6736(05)67176-0</mixed-citation></ref><ref id="scirp.115079-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Dondorp, A.M., Fanello, C.I., Hendriksen, I.C.E., Gomes, E., Seni, A., Chhaganlal, K.D., et al. (2010) Artesunate versus Quinine in the Treatment of Severe Falciparum Malaria in African Children (AQUAMAT): An Open-Label, Randomised Trial. The Lancet, 376, 1647-1657. https://doi.org/10.1016/S0140-6736(10)61924-1</mixed-citation></ref><ref id="scirp.115079-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Paczkowski, M.M., Landman, K.L. and Arguin, P.M. (2014) Update on Causes of Delayed Hemolysis after Parenteral Artesunate Therapy for Malaria—United States, 2008-2013. MMWR, 63, 753-755.</mixed-citation></ref><ref id="scirp.115079-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Vachon, F., Fajac, I., Gachot, B., Coulaud, J.P. and Charmot, G. (1992) Halofantrine and Acute Intravascular Haemolysis. The Lancet, 340, 909-910. https://doi.org/10.1016/0140-6736(92)93317-G</mixed-citation></ref><ref id="scirp.115079-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Mojon, M., Wallon, M., Gravey, A., Peaud, P.Y., Sartre, J. and Peyron, F. (1994) Intravascular Haemolysis Following Halofantrine Intake. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88, 91. https://doi.org/10.1016/0035-9203(94)90516-9</mixed-citation></ref><ref id="scirp.115079-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Lon, C., Spring, M., Sok, S., Chann, S., Bun, R., Ittiverakul, M., et al. (2014) Black Water Fever in an Uncomplicated Plasmodium falciparum Patient Treated with Dihydroartemisinin-Piperaquine. Malaria Journal, 13, Article No. 96. https://doi.org/10.1186/1475-2875-13-96</mixed-citation></ref><ref id="scirp.115079-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sher, A., Iqbal, J., Hira, P.R., Owaish, R.A. and Anezi, A.A. (1996) Rapid Diagnosis of Malaria by Antigen-Capture Method. Proceedings of the 10th Scientific Congress of the Kuwait Medical Association, Kuwait City, November 1996, 46-49.</mixed-citation></ref><ref id="scirp.115079-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sher, A. and Latf, S.A. (2021) Congenital Malaria: First Case Report in Kuwait. Advances in Infectious Diseases, 11, 290-297. https://doi.org/10.4236/aid.2021.113026</mixed-citation></ref><ref id="scirp.115079-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Oumar, A.A., Poudiougou, B., Sylla, M., et al. (2007) Black Water Fever in Children during Cerebral Malaria: 3 Case-Reports in Bamako. Archives de Pédiatrie, 14, 993-995. https://doi.org/10.1016/j.arcped.2007.04.005</mixed-citation></ref><ref id="scirp.115079-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Hue, N.T., Charlieu, J.P., Chau, T.T., Day, N., Farrar, J.J., Hien, T.T., et al. (2009) Glucose-6-Phosphate Dehydrogenase (G6PD) Mutations and Haemoglobinuria Syndrome in the Vietnamese Population. Malaria Journal, 8, Article No. 152. https://doi.org/10.1186/1475-2875-8-152</mixed-citation></ref><ref id="scirp.115079-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Chotivanich, K., Udomsangpetch, R., McGready, R., Proux, S., Newton, P., Pukrittayakamee, S., et al. (2002) Central Role of the Spleen in Malaria Parasite Clearance. The Journal of Infectious Diseases, 185, 1538-1541. https://doi.org/10.1086/340213</mixed-citation></ref></ref-list></back></article>